SAN DIEGO, Nov. 19 /PRNewswire/ -- ChemDiv, Inc. and Nerviano Medical Sciences S.r.l. today announced that they have entered into a collaboration to optimize and develop hits for Nerviano’s drug targets.
The new agreement follows a successful collaboration since 2004. The hits identified from NMS HT screening campaign will be optimized in terms of their potency, selectivity, in-vitro ADME profile with the subsequent progression into a lead optimisation program. A dedicated team of ChemDiv’s chemists and biologists will work on this program in close collaboration with NMS. ChemDiv will receive fees for services carried out and milestone payment for the successful performance of the program. Financial terms and Nerviano’s drug targets were not disclosed.
“We have decided to extend our collaboration with ChemDiv because of their professionalism and top quality capabilities in chemistry. This new agreement is a significant step forward in the exploitation of our project pipeline. We believe ChemDiv contribution will represent a major upside in our commitment to push into the clinic high quality chemical candidates intended to inhibit key cancer molecular targets”, said Giampiero Duglio, NMS’ CEO.
Nikolay Savchuk, President and CEO of ChemDiv, Inc. commented: “We are proud to have been working with NervianoMS since 2004 as a preferred chemistry partner. This new collaboration expands our successful partnership with NervianoMS into another area ChemDiv’s Discovery outSourceTM platform, including proprietary rational design, extensive medicinal chemistry and pre-clinical biology capabilities. We are confident that ChemDiv’s research will contribute an increased value to Nerviano’s drug discovery programs.”
About Nerviano Medical Sciences
Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development organizations in Europe. It was incorporated in May 2004 following a spin-off from Pfizer. Today NMS is a private company in Italy, wholly owned by the Rome based Congregazione dei Figli dell’Immacolata Concezione (CFIC). NMS employs approximately 650 scientists and managers organized into three integrated Business Units: Oncology, Preclinical Development and Pharmaceutical Sciences. For additional information, please visit http://www.nervianoms.com and also http://www.accelera.info
About ChemDiv, Inc.
ChemDiv (http://www.chemdiv.com) is a global chemistry-driven contract research organization focused on identifying and delivering pre-clinical opportunities and services to life science partners for the treatment of life-threatening diseases. Over 17 years ChemDiv provides Discovery outSourceTM solutions including medicinal and synthetic chemistry, pre-clinical development, screening libraries and global logistics. ChemDiv international research team encompasses 550 chemists and biologists in San Diego and Moscow based R&D centers.
CONTACT: Ron Demuth, General Manager of ChemDiv, Inc., +1-858-794-4860,
fax, +1-858-794-4931, rd@chemdiv.com; or Maria D’Acquino, Public Affairs
and Communications of Nerviano Medical Sciences, +39 0331 581013, fax, +39
0331 581370, maria.dacquino@nervianoms.com
Web site: http://www.chemdiv.com/
http://www.nervianoms.com/
http://www.accelera.info/
